Vanda Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 7, 2012

Conference Call and Webcast to Follow

WASHINGTON, Oct. 17, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for the third quarter of 2012 on Wednesday, November 7, 2012, before the market opens.

The Company will host a conference call at 10:00 AM ET on Wednesday, November 7, 2012, during which Vanda management will discuss the financial results.  To participate in the conference call, please dial 1-800-299-7089 (domestic) or 1-617-801-9714 (international) and use passcode 66514556.

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, November 7, 2012, beginning at 12:00 PM ET and will be accessible until Wednesday, November 14, 2012, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The passcode number is 34968750.

ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:          
Cristina Murphy
Senior Communications Manager                      
Vanda Pharmaceuticals Inc.                              
(202) 734-3400                                                              
[email protected]  

SOURCE Vanda Pharmaceuticals Inc.

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.